Ruolo terapeutico e profilattico della mesalazina (5-ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow-up

Translated title of the contribution: Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow-up results

E. Trespi, C. Colla, P. Panizza, M. G. Polino, A. Venturini, G. Bottani, P. De Vecchi, C. Matti

Research output: Contribution to journalArticlepeer-review

Abstract

In order to evaluate the efficacy and tolerability of mesalazine (5-ASA) in the prophylaxis of simptomatic relapses, of major complications and of microhemmorrhagic phenomena in diverticular disease of the large intestine (MDC), prospective clinical study was conducted on patients with light- moderate symptomatic MDC under treatment with sulbactam-ampicillin 1.5 g/12 h.i.m. and rifaximine 400 mg/12 h per os for 7 days. Follow-up period of 5 years with seriated checkups and laboratory and instrumentation controls. End points are represented by the relapse on inflammation and/or by the occurrence of major complications. On enrolment, 166 patients were randomized to receive mesalazine (Pentacol® tablets - SOFAR S.p.A.) 400 mg b.i.d. per os for 8 weeks (81 patients; group M) or no supplementary treatment (85 patients; group C). After 4 years of follow-up, 44 patients dropped out of the study (9 because of major complications, 3 for massive hemorrhage, and 32 drop outs). Symptomatic relapses occurred in 51 patients (12 M; 39 C), while minor diverticular hemorrhages occurred in 43 patients (12 M; 31 C), with an estimated probability of remaining free respectively from symptomatic relapse (p=0.00005) and from microhemorrhagic phenomena (p=0.001) decisively in favor of the group treated with mesalazine. The duration of abdominal pain due to diverticolitis was also shorter in patients of group M (p=0.0002), while the incidence of major complications and side effects was comparable in the two groups. In conclusion, supplementary treatment with mesalazine in patients affected with MDC - at a follow-up limited to 48 months - proved to be well tolerated and effective in reducing the frequency of symptomatic relapses and microhemorrhagic phenomena and in reducing the duration of abdominal pain.

Translated title of the contributionTherapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow-up results
Original languageItalian
Pages (from-to)245-252
Number of pages8
JournalMinerva Gastroenterologica e Dietologica
Volume45
Issue number4
Publication statusPublished - 1999

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow-up results'. Together they form a unique fingerprint.

Cite this